drugset
drugset / Trial / NCT06650332

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

NCT06650332 ↗

Phase 1/2 Recruiting 90 enrolled Zhejiang Cancer Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This trial is An open-label, multicohort, multicenter clinical study aimed at evaluating the efficacy and safety of the cadonilimab combination regimen in the treatment of advanced HER-2 positive gastric/gastroesophageal junction tumors

Timeline

Start
2024-07-10
Primary completion
2026-08-10
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Cadonilimab Monoclonal antibody 6 mg/kg Intravenous
Subject Cadonilimab Monoclonal antibody 10 mg/kg Intravenous
Subject Disitamab Vedotin Monoclonal antibody 1.5 mg/kg Intravenous
Subject Disitamab Vedotin Monoclonal antibody 2 mg/kg Intravenous
Subject Disitamab Vedotin Monoclonal antibody 2.5 mg/kg Intravenous
Subject Trastuzumab Monoclonal antibody 6 mg/kg Intravenous
Background Capecitabine Small molecule 1000 mg/m2 Oral
Background Leucovorin Small molecule 400 mg/m2 Intravenous
Background Oxaliplatin Small molecule 85 mg/m2 Intravenous
Background Oxaliplatin Small molecule 130 mg/m2 Intravenous
Background fluorouracil Small molecule 2400 mg/m2 Intravenous

Indications

gastroesophageal cancer